Nectar Lifesciences (NSE:NECLIFE) Cyclically Adjusted Book per Share: ₹59.93 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NECLIFE Nectar Lifesciences Ltd NSE:NECLIFE
51 GF Score
Price ₹10.55
GF Value ₹6.86
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nectar Lifesciences Cyclically Adjusted Book per Share?

Nectar Lifesciences NSE:NECLIFE -1.40% 51 Cyclically Adjusted Book per Share is ₹59.93 as of Mar. 2026. GuruFocus rates NSE:NECLIFE with a GF Score™ of 51/100 and a GF Value™ of ₹6.86 (Significantly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Nectar Lifesciences's adjusted book value per share for the three months ended in Mar. 2026 was ₹29.975. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₹59.93 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Nectar Lifesciences's average Cyclically Adjusted Book Growth Rate was 0.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-23), Nectar Lifesciences's current stock price is ₹10.55. Nectar Lifesciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was ₹59.93. Nectar Lifesciences's Cyclically Adjusted PB Ratio of today is 0.18.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nectar Lifesciences was 0.45. The lowest was 0.17. And the median was 0.24.


Nectar Lifesciences  (NSE:NECLIFE) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Nectar Lifesciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=10.55/59.93
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nectar Lifesciences was 0.45. The lowest was 0.17. And the median was 0.24.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Nectar Lifesciences Cyclically Adjusted Book per Share Related Terms


Nectar Lifesciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Nectar Lifesciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nectar Lifesciences Cyclically Adjusted Book per Share Chart

Nectar Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 59.53 59.93

Nectar Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.53 0.00 60.40 0.00 59.93

NSE:NECLIFE vs ZTS, UTHR: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nectar Lifesciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nectar Lifesciences's Cyclically Adjusted PB Ratio falls into.


NSE:NECLIFE
51GF Score
Nectar Lifesciences Ltd NSE:NECLIFE
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nectar Lifesciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nectar Lifesciences's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=29.975/164.2724*164.2724
=29.975

Current CPI (Mar. 2026) = 164.2724.

Nectar Lifesciences Quarterly Data

Book Value per Share CPI Adj_Book
201103 32.156 70.768 74.643
201203 34.980 76.889 74.735
201303 38.687 85.687 74.168
201403 41.338 91.425 74.276
201503 40.222 97.163 68.003
201603 42.543 102.518 68.170
201703 44.889 105.196 70.098
201803 47.207 109.786 70.635
201806 0.000 111.317 0.000
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 49.280 118.202 68.487
201906 0.000 120.880 0.000
201909 49.943 123.175 66.607
201912 0.000 126.235 0.000
202003 50.661 124.705 66.735
202006 0.000 127.000 0.000
202009 49.525 130.118 62.525
202012 0.000 130.889 0.000
202103 47.357 131.771 59.038
202106 0.000 134.084 0.000
202109 47.520 135.847 57.463
202112 0.000 138.161 0.000
202203 48.511 138.822 57.405
202206 0.000 142.347 0.000
202209 47.684 144.661 54.148
202212 0.000 145.763 0.000
202303 47.471 146.865 53.098
202306 0.000 150.280 0.000
202309 47.598 151.492 51.614
202312 0.000 152.924 0.000
202403 47.679 153.035 51.180
202406 0.000 155.789 0.000
202409 48.061 157.882 50.006
202412 0.000 158.323 0.000
202503 42.634 157.552 44.453
202506 0.000 159.755 0.000
202509 31.966 162.289 32.357
202512 0.000 163.281 0.000
202603 29.975 164.272 29.975

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ₹59.93 mean?
Nectar Lifesciences (NSE:NECLIFE) has a Cyclically Adjusted Book per Share of ₹59.93 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Nectar Lifesciences and its competitors.
Is Nectar Lifesciences' Cyclically Adjusted Book per Share too high?
Nectar Lifesciences' current Cyclically Adjusted Book per Share is ₹59.93. Overall, Nectar Lifesciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nectar Lifesciences' Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Nectar Lifesciences' Cyclically Adjusted Book per Share of ₹59.93 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Nectar Lifesciences and its competitors. Nectar Lifesciences's current Cyclically Adjusted Book per Share is ₹59.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nectar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Nectar Lifesciences (NSE:NECLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.86, compared to a current price of ₹10.55 — trading 53.8% above its estimated fair value. The current Cyclically Adjusted Book per Share is ₹59.93. Nectar Lifesciences' overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Nectar Lifesciences (NSE:NECLIFE), the current Cyclically Adjusted Book per Share is ₹59.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued. The current stock price of ₹10.55 is trading 53.8% above its estimated GF Value™ of ₹6.86. GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.

Key valuation signals for NSE:NECLIFE:

  • Cyclically Adjusted Book per Share: ₹59.93
  • GF Value™: ₹6.86 vs. price of ₹10.55 (53.8% above fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nectar Lifesciences Business Description

Other Exchanges 532649:India
Address S.C.O. 38-39, Sector 9-D, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
51GF Score

Get the complete analysis for NSE:NECLIFE

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹10.55
Price
₹6.86
GF Value